We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,177.25 +9.75 (+0.19%) Dow Futures
38,299.00 +61.00 (+0.16%) Nasdaq Futures
18,218.25 +39.00 (+0.21%) Russell 2000 Futures
2,028.80 +9.00 (+0.45%) Crude Oil
85.40 -0.26 (-0.30%) Gold
2,369.20 -4.90 (-0.21%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 107.01 |
| Open | 106.00 |
| Bid | 105.13 x 200 |
| Ask | 105.20 x 200 |
| Day's Range | 104.65 - 107.88 |
| 52 Week Range | 62.55 - 156.75 |
| Volume | |
| Avg. Volume | 3,933,008 |
| Market Cap | 40.256B |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -12.33 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 123.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MRNA
Related Research
- Moderna, Inc.Mid Cap U.S. Pick List March 2024This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.RatingFair ValueEconomic Moatlast monthMorningstar
Simply Wall St.Investing in Moderna (NASDAQ:MRNA) five years ago would have delivered you a 367% gain
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...
ZacksThe Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
Motley Fool1 New Green Flag for Moderna and Merck Stock
There's a new reason to believe that their joint projects are going well.
ZacksModerna (MRNA) Stock Dips While Market Gains: Key Facts
Moderna (MRNA) closed the most recent trading day at $107.01, moving -0.12% from the previous trading session.
- Reuters
UPDATE 3-Moderna pauses Kenya plant plans as COVID vaccine demand wanes
Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines. The move is in line with Moderna's strategy of resizing its manufacturing network to cut costs, even as it aims to spend around $4.5 billion this year in research and development of several new vaccines, including for cancer and respiratory syncytial virus (RSV). Many of the messenger RNA (mRNA) vaccines that Moderna is developing, like for HIV and malaria, are at an early stage.
ZacksBiotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
BenzingaThe Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: JNJ) are facing the so-called patent cliffs which imply revenue of tens of billions of dollars between now and and the end of this decade is at risk. The expiration of patents for one or more leading branded products for a company means opening the door to competitors to sell copycats of those drugs, often at a competitive price. But, as always, pharmaceutical companies do their best
Investor's Business DailyIs Moderna Stock A Buy After Rallying, Briefly, On Fresh Cancer Vaccine News?
Moderna stock rallied after the company unveiled head-and-neck cancer treatment data. Is MRNA stock a buy or a sell right now?
ZacksModerna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.
Morningstar Rating
Rating
Fair Value
Economic Moat
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| NVAX Novavax, Inc. | |||
| BNTX BioNTech SE | |||
| ZM Zoom Video Communications, Inc. | |||
| NIO NIO Inc. | |||
| INO Inovio Pharmaceuticals, Inc. |
Similar to MRNA
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| ALPN Alpine Immune Sciences, Inc. | |||
| VRTX Vertex Pharmaceuticals Incorporated | |||
| NVAX Novavax, Inc. | |||
| BNTX BioNTech SE | |||
| NVO Novo Nordisk A/S |
Analyst Price Targets (19)
Upgrades & Downgrades
| Reiterates | Needham: to Hold | 4/11/2024 | |
| Reiterates | Jefferies: Buy to Buy | 4/9/2024 | |
| Reiterates | RBC Capital: Outperform to Outperform | 3/28/2024 | |
| Reiterates | Needham: to Hold | 3/28/2024 | |
| Downgrade | HSBC: Hold to Reduce | 2/26/2024 | |
| Reiterates | RBC Capital: Outperform to Outperform | 2/23/2024 |
Company Profile
200 Technology Square
Cambridge, MA 02139
United States
617 714 6500
https://www.modernatx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 5,600
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
